Vitas Pharma's primary focus is develop therapies that target the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter sp). These organisms are responsible for serious hospital acquired infections, such as complicated urinary tract infections, hospital acquired pneumonia, blood stream infections and skin and soft tissue infections.
Vitas Pharma's compounds are novel chemical scaffolds that target critical pathways in bacteria. They are selected from custom built virtual libraries of compounds screened against in silico structural models of bacterial proteins. Iterative rounds of chemical modification and biological testing through Vitas' proprietary platform Tackling Antimicrobial Resistance through Novel Scaffolds (TARNS), lead to optimized structures with in vitro and in vivo activity.